China’s fourth richest man takes a back seat at the top drugmaker he built

Amber Tong

After spending the past 30 years transforming Jiangsu Hengrui Medicines from just another manufacturer of dirt cheap over-the-counter pills to a top 25 global …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China’s fourth richest man takes a back seat at the top drugmaker he built

Amber Tong

Sign up to read this article for free.

What will pharma's share buyback shopping spree mean for M&A?

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Chi­na’s fourth rich­est man takes a back seat at the top drug­mak­er he built

Amber Tong

Sign up to read this article for free.

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

IN8bio’s Phase 1 AML da­ta; Lay­offs at Q32 Bio and Third Har­mon­ic

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

China’s fourth richest man takes a back seat at the top drugmaker he built

What will pharma's share buyback shopping spree mean for M&A?

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers